Synthesis of ATP derivatives of compounds of the mevalonate pathway (isopentenyl di- and triphosphate; geranyl di- and triphosphate, farnesyl di- and triphosphate, and dimethylallyl diphosphate) catalyzed by T4 RNA ligase, T4 DNA ligase and other ligases. Potential relationship with the effect of bisphosphonates on osteoclasts

Biochemical Pharmacology

Volumn 78, Issue 4, 2009, Pages 335-343

  Sillero, Maria A Günther ^a   de Diego, Anabel ^a   Tavares, Janeth E F ^a   Silva, Joana A D Catanho da ^a   Pérez Zúñiga, Francisco J ^a   Sillero, Antonio ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

Bisphosphonates; Bone; Mevalonate; Osteoclasts; Osteoporosis

Indexed keywords

ACYL COENZYME A; ADENOSINE TRIPHOSPHATE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; DIMETHYLALLYL DIPHOSPHATE; FARNESYL DIPHOSPHATE; FARNESYL TRIPHOSPHATE; FIREFLY LUCIFERASE; GERANYL DIPHOSPHATE; GERANYL TRIPHOSPHATE; ISOPENTENYL DIPHOSPHATE; ISOPENTENYL TRIPHOSPHATE; MEVALONIC ACID; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RNA LIGASE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION PROCESS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME MECHANISM; ENZYME SUBSTRATE; ENZYME SYNTHESIS; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANIMALS; BINDING SITES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPHOSPHATES; DIPHOSPHONATES; DITERPENES; DNA LIGASES; HEMITERPENES; MEVALONIC ACID; ORGANOPHOSPHORUS COMPOUNDS; OSTEOCLASTS; POLYISOPRENYL PHOSPHATES; POLYPHOSPHATES; RNA LIGASE (ATP); SESQUITERPENES; SUBSTRATE SPECIFICITY;

EID: 67349095795     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.04.028     Document Type: Article

References (35)

1. Bartl R., Frisch B., von Tresckow E., and Bartl C. Bisphosphonates in medical practice (2007), Springer-Verlag, Berlin
2. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18 (1996) 75-85
3. Chen T., Berenson J., Vescio R., Swift R., Gilchick A., Goodin S., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42 (2002) 1228-1236
4. Skerjanec A., Berenson J., Hsu C., Major P., Miller Jr. W.H., Ravera C., et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 43 (2003) 154-162
5. 3-methylenetetraphosphate) . Biochemistry 27 (1988) 1897-1901
6. Rogers M.J., Brown R.J., Hodkin V., Blackburn G.M., Russell R.G., and Watts D.J. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 224 (1996) 863-869
7. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9 (2003) 2643-2658
8. Günther Sillero M.A., de Diego A., Silles E., Pérez-Zúñiga F., and Sillero A. Synthesis of bisphosphonate derivatives of ATP by T4 RNA ligase. FEBS Lett 580 (2006) 5723-5727
9. Günther Sillero M.A., de Diego A., Pérez-Zúñiga F.J., and Sillero A. Synthesis of bisphosphonate derivatives of ATP by T4 DNA ligase, ubiquitin activating enzyme (E1) and other ligases. Biochem Pharmacol 75 (2008) 1959-1965
10. Reszka A.A., and Rodan G.A. Bisphosphonate mechanism of action. Curr Rheumatol Rep 5 (2003) 65-74
11. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., and Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373 (2000) 231-241
12. Rogers M.J. New insights into the molecular actions of nitrogen-containing bisphosphonates. Haematol Rep 2 (2006) 24-25
13. Amin D., Cornell S.A., Gustafson S.K., Needle S.J., Ullrich J.W., Bilder G.E., et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33 (1992) 1657-1663
14. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., Hughes D.E., Masarachia P.J., et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96 (1999) 133-138
15. Roelofs A.J., Thompson K., Gordon S., and Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12 (2006) 6222s-6230s
16. Mönkkönen H., Auriola S., Lehenkari P., Kellinsalmi M., Hassinen I.E., Vepsalainen J., et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 147 (2006) 437-445
17. Lehenkari P.P., Kellinsalmi M., Napankangas J.P., Ylitalo K.V., Mönkkönen J., Rogers M.J., et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61 (2002) 1255-1262
18. Sillero A., and Günther Sillero M.A. Synthesis of dinucleoside polyphosphates catalyzed by firefly luciferase and several ligases. Pharmacol Ther 87 (2000) 91-102
19. Ortiz B., Sillero A., and Günther Sillero M.A. Specific synthesis of adenosine(5′)tetraphospho(5′)nucleoside and adenosine(5′)oligophospho(5′)adenosine (n > 4) catalyzed by firefly luciferase. Eur J Biochem 212 (1993) 263-270
20. Fontes R., Günther Sillero M.A., and Sillero A. Acyl coenzyme A synthetase from Pseudomonas fragi catalyzes the synthesis of adenosine 5'-polyphosphates and dinucleoside polyphosphates. J Bacteriol 180 (1998) 3152-3158
21. Guranowski A., Günther Sillero M.A., and Sillero A. Adenosine 5′-tetraphosphate and adenosine 5′-pentaphosphate are synthesized by yeast acetyl coenzyme A synthetase. J Bacteriol 176 (1994) 2986-2990
22. Günther Sillero M.A., de Diego A., Silles E., and Sillero A. Synthesis of (di)nucleoside polyphosphates by the ubiquitin activating enzyme E1. FEBS Lett 579 (2005) 6223-6229
23. 4A and other dinucleoside polyphosphates (1992), CRC Press, Boca Raton, Florida
24. McLennan A.G., Barnes L.D., Blackburn G.M., Brenner C., Guranowski A., Miller A.D., et al. Recent progress in the study of the intracellular functions of diadenosine polyphosphates. Drug Dev Res 52 (2001) 249-259
25. Delicado E.G., Miras-Portugal M.T., Carrasquero L.M., León D., Pérez-Sen R., and Gualix J. Dinucleoside polyphosphates and their interaction with other nucleotide signaling pathways. Pflugers Arch 452 (2006) 563-572
26. 4A and other dinucleoside polyphosphates (1992), CRC Press, Boca Raton, Florida 9-28
27. Madrid O., Martin D., Atencia E.A., Sillero A., and Günther Sillero M.A. T4 DNA ligase synthesizes dinucleoside polyphosphates. FEBS Lett 433 (1998) 283-286
28. Atencia E.A., Madrid O., Günther Sillero M.A., and Sillero A. T4 RNA ligase catalyzes the synthesis of dinucleoside polyphosphates. Eur J Biochem 261 (1999) 802-811
29. DeLuca M., and McElroy W.D. The hydrolase properties of firefly luciferase. Biochem Biophys Res Commun 18 (1965) 836-842
30. 4N). Synthesis with firefly luciferase. J Biochem Biophys Methods 30 (1995) 191-198
31. Hosfield D.J., Zhang Y., Dougan D.R., Broun A., Tari L.W., Swanson R.V., et al. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J Biol Chem 279 (2004) 8526-8529
32. Kavanagh K.L., Guo K., Dunford J.E., Wu X., Knapp S., Ebetino F.H., et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 103 (2006) 7829-7834
33. Rondeau J.M., Bitsch F., Bourgier E., Geiser M., Hemmig R., Kroemer M., et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. Chem Med Chem 1 (2006) 267-273
34. Buitrago F., Canales J., Günther Sillero M.A., and Sillero A. Occurrence of a novel nucleotide, Zpp5'A2'p, in rat liver extracts. Biochem Int 16 (1988) 175-184
35. Sillero M.A.G., Villalba R., Moreno A., Quintanilla M., Lobatón C.D., and Sillero A. Dinucleosidetriphosphatase from rat liver. Purification and properties. Eur J Biochem 76 (1977) 331-337